Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 12:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 6,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 1 Clear all

Conditions: Urinary Incontinence
Interventions: Academic Detailing, Electronic Clinical Decision Support, APP Co-management, Electronic Referral; Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 1,600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: La Jolla, California • Los Angeles, California • Torrance, California

Conditions: Cirrhosis, Ascites, Liver Diseases, Frailty, Sarcopenia, Hepatic Encephalopathy
Interventions: Medically-tailored meals (MTM), Protein supplements, Nutrition education handout; Other · Dietary Supplement · Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: HIV
Interventions: Raltegravir; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 99 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Eating Disorder Symptom, Body Image Disturbance
Interventions: Mirror exposure and text prompt responses; Behavioral
Lead sponsor: Union College, New York; Other
Eligibility: 18 Years and older · Female only
Enrollment: 275 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Albany, New York • Schenectady, New York

Conditions: Psoriatic Arthritis
Interventions: methotrexate (MTX), adalimumab (ADA); Drug · Biological
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 12
States / cities: Sun City, Arizona • Miami, Florida • Vernon Hills, Illinois + 9 more

Conditions: Dietary Intervention, Produce Prescription, Chronic Disease Management, Social Needs Screening
Interventions: Culturally Tailored Cooking Classes, Prescription Produce Plan; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Hypertension, Stress, Psychological
Interventions: Caregiver Training; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 40 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Multiple Myeloma, Plasma Cell Leukemia
Interventions: ARRY-520, KSP(Eg5) inhibitor; intravenous, Bortezomib, proteasome inhibitor; intravenous or subcutaneous, Dexamethasone, steroid; oral, Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous; Drug
Lead sponsor: Array Biopharma, now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 13
States / cities: Huntsville, Alabama • Tucson, Arizona • Duarte, California + 9 more

Conditions: Healthy
Interventions: Seltorexant High Dose, Seltorexant Low Dose; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 151 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Focal Epilepsy, Temporal Lobe Epilepsy, Medically Refractory Epilepsy, Memory Disorders, Epilepsy Comorbidities, Epilepsy Intractable, Epilepsy Surgery, Epilepsy, Temporal Lobe, Memory Deficits, Memory Disorder, Spatial, Memory Dysfunction, Spatial Perception
Interventions: Virtual Tour Recognition Memory Task, Intracranial EEG Recording with Research Electrodes (Aim III only), MRI Neuroimaging and Neuropsychological Assessment (Aim I); Behavioral · Device · Diagnostic Test
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 55 Years
Enrollment: 620 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2030
U.S. locations: 2
States / cities: Sacramento, California • Atlanta, Georgia

Conditions: Peripheral Pulmonary Lesions (PPLs), Lung Nodules
Interventions: Bronchoscopy for peripheral pulmonary lesion biopsy; Procedure
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Chicago, Illinois • Cleveland, Ohio

Conditions: SARS-CoV-2
Interventions: mRNA-1273; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 15
States / cities: Mesa, Arizona • San Diego, California • New Haven, Connecticut + 12 more

Conditions: Cellulitis
Interventions: Dermatology consult; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cord Compression
Interventions: Radiation therapy, nab-Paclitaxel; Radiation · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Total Knee Replacement, Genicular Nerve Block, Opioid Use
Interventions: Bupivacaine Injection, Dexamethasone injection, Fentanyl, Mepivacaine; Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 80 Years
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: LY3537982, Digoxin, Rosuvastatin, Midazolam; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Influenza, Otitis Media, Lower Resp Tract Infection, Encephalitic Infection, Myositis Viral, Fever
Interventions: Respiratory nasal swab; Procedure
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 6 Months to 8 Years
Enrollment: 1,478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Aurora, Colorado • Broomfield, Colorado

Conditions: Weight Gain
Interventions: Prenatal yoga, Pregnancy education; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years to 46 Years · Female only
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Phoenix, Arizona

Conditions: Hepatitis C
Interventions: TMC435, Ribavirin (R), PegIFNα-2a (P), Placebo; Drug
Lead sponsor: Tibotec Pharmaceuticals, Ireland; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 12
States / cities: Los Angeles, California • Jacksonville, Florida • Orlando, Florida + 9 more

Conditions: Advanced Solid Tumors
Interventions: GS-3583, Zimberelimab, Cisplatin, Carboplatin, 5-Fluorouracil, Docetaxel; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Grand Rapids, Michigan • New York, New York • Portland, Oregon + 1 more

Conditions: Depression, Anxiety, PTSD, Fibromyalgia, Chronic Fatigue Syndrome
Interventions: High intensity whole-body infrared heating; Device
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Ewing Sarcoma, Sarcoma
Interventions: Mithramycin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Overweight, Obesity, Type 2 Diabetes
Interventions: Tirzepatide, Zenagamtide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Idiopathic Hypersomnia
Interventions: ALKS 2680, Placebo; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 34
States / cities: Cullman, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 31 more

Search by objective public record fields.

A Practice-Based Intervention To Improve Care for a Diverse Population Of Women With Urinary Incontinence

The BRAINFOOD Trial to Prevent Recurrent Hepatic Encephalopathy.

Addition of Raltegravir to Established Antiretroviral Suppressive Therapy

In the Mirror: Functional Appreciated Bodies (IM FAB)

A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

Promoting Nutrition Security and Chronic Disease Management Through a Produce Prescription Program

Stress and Hypertension in Dementia Caregivers

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

A Study of Seltorexant (JNJ-42847922) After Single-Dose Administration in Healthy Participants

Spatial Scene Recognition Memory in Epilepsy Surgery

Shape-sensing Versus Electromagnetic Robotic Bronchoscopy for Evaluation of PulmoNary LEsions

A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants

Study Assessing Impact of Dermatology Consultation for Patients Admitted With Cellulitis

Pulsed Abraxane and Radiotherapy for Improving and Maintaining Ambulation After Cancer-Related Cord Compression

Genicular and Anterior Femoral Cutaneous Nerve Blocks for Total Knee Arthroplasty

A Drug-Drug Interaction Study of LY3537982 on Midazolam, Digoxin, and Rosuvastatin in Healthy Participants

Evaluation of Moderate to Severe Influenza Outcomes in Children

Investigating the Feasibility and Preliminary Effects of Yoga on Excessive Gestational Weight Gain

A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment

Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors

Whole Body Hyperthermia Registry Study

Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma

A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia